Second-Quarter 2022 Results: Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Milli.
Form 8-K Horizon Therapeutics For: Apr 28 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Teprotumumab is marketed under the brand name TEPEZZA in the United States Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical